Geron Corporation (GERN) - Net Assets
Based on the latest financial reports, Geron Corporation (GERN) has net assets worth $248.71 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($567.38 Million) and total liabilities ($318.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Geron Corporation's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $248.71 Million |
| % of Total Assets | 43.83% |
| Annual Growth Rate | 9.24% |
| 5-Year Change | 32.89% |
| 10-Year Change | 97.23% |
| Growth Volatility | 74.14 |
Geron Corporation - Net Assets Trend (1996–2024)
This chart illustrates how Geron Corporation's net assets have evolved over time, based on quarterly financial data. Also explore GERN asset base for the complete picture of this company's asset base.
Annual Net Assets for Geron Corporation (1996–2024)
The table below shows the annual net assets of Geron Corporation from 1996 to 2024. For live valuation and market cap data, see Geron Corporation stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $280.32 Million | +13.06% |
| 2023-12-31 | $247.95 Million | +209.94% |
| 2022-12-31 | $80.00 Million | -36.72% |
| 2021-12-31 | $126.42 Million | -40.07% |
| 2020-12-31 | $210.95 Million | +56.08% |
| 2019-12-31 | $135.16 Million | -23.96% |
| 2018-12-31 | $177.73 Million | +71.23% |
| 2017-12-31 | $103.80 Million | -15.18% |
| 2016-12-31 | $122.38 Million | -13.89% |
| 2015-12-31 | $142.13 Million | +8.73% |
| 2014-12-31 | $130.71 Million | +118.74% |
| 2013-12-31 | $59.76 Million | -30.23% |
| 2012-12-31 | $85.65 Million | -41.57% |
| 2011-12-31 | $146.60 Million | -23.94% |
| 2010-12-31 | $192.74 Million | +11.68% |
| 2009-12-31 | $172.58 Million | +2.45% |
| 2008-12-31 | $168.46 Million | -18.10% |
| 2007-12-31 | $205.67 Million | +18.26% |
| 2006-12-31 | $173.92 Million | -8.80% |
| 2005-12-31 | $190.71 Million | +56.23% |
| 2004-12-31 | $122.06 Million | +14.80% |
| 2003-12-31 | $106.32 Million | +257.50% |
| 2002-12-31 | $29.74 Million | -51.67% |
| 2001-12-31 | $61.54 Million | -3.72% |
| 2000-12-31 | $63.92 Million | +143.96% |
| 1999-12-31 | $26.20 Million | -20.12% |
| 1998-12-31 | $32.80 Million | +55.45% |
| 1997-12-31 | $21.10 Million | -10.59% |
| 1996-12-31 | $23.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Geron Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 173584100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $606.00K | 0.22% |
| Other Comprehensive Income | $261.00K | 0.09% |
| Other Components | $2.05 Billion | 731.95% |
| Total Equity | $280.32 Million | 100.00% |
Geron Corporation Competitors by Market Cap
The table below lists competitors of Geron Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing UniStrong Science & Technology Co Ltd
SHE:002383
|
$1.01 Billion |
|
Tian Jin Motor Dies Co Ltd
SHE:002510
|
$1.01 Billion |
|
UP FINT. HLDG (SP.ADR) A
F:1M5
|
$1.01 Billion |
|
Daoming Optics&Chemical Co Ltd
SHE:002632
|
$1.01 Billion |
|
Changsha DIALINE New Material Sci & Tech Co Ltd
SHE:300700
|
$1.01 Billion |
|
Shentong Technology Group Co Ltd
SHG:605228
|
$1.01 Billion |
|
Planisware SAS
PA:PLNW
|
$1.01 Billion |
|
Indocement Tunggal Prakarsa
JK:INTP
|
$1.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Geron Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 247,949,000 to 280,320,000, a change of 32,371,000 (13.1%).
- Net loss of 174,572,000 reduced equity.
- New share issuances of 140,729,000 increased equity.
- Other comprehensive income increased equity by 76,000.
- Other factors increased equity by 66,138,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-174.57 Million | -62.28% |
| Share Issuances | $140.73 Million | +50.2% |
| Other Comprehensive Income | $76.00K | +0.03% |
| Other Changes | $66.14 Million | +23.59% |
| Total Change | $- | 13.06% |
Book Value vs Market Value Analysis
This analysis compares Geron Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.64x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.52x to 3.64x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $3.05 | $1.58 | x |
| 1997-12-31 | $2.00 | $1.58 | x |
| 1998-12-31 | $2.87 | $1.58 | x |
| 1999-12-31 | $1.69 | $1.58 | x |
| 2000-12-31 | $3.06 | $1.58 | x |
| 2001-12-31 | $2.78 | $1.58 | x |
| 2002-12-31 | $1.21 | $1.58 | x |
| 2003-12-31 | $3.43 | $1.58 | x |
| 2004-12-31 | $2.72 | $1.58 | x |
| 2005-12-31 | $3.29 | $1.58 | x |
| 2006-12-31 | $2.63 | $1.58 | x |
| 2007-12-31 | $2.77 | $1.58 | x |
| 2008-12-31 | $2.15 | $1.58 | x |
| 2009-12-31 | $1.96 | $1.58 | x |
| 2010-12-31 | $1.97 | $1.58 | x |
| 2011-12-31 | $1.18 | $1.58 | x |
| 2012-12-31 | $0.67 | $1.58 | x |
| 2013-12-31 | $0.47 | $1.58 | x |
| 2014-12-31 | $0.85 | $1.58 | x |
| 2015-12-31 | $0.87 | $1.58 | x |
| 2016-12-31 | $0.77 | $1.58 | x |
| 2017-12-31 | $0.65 | $1.58 | x |
| 2018-12-31 | $1.01 | $1.58 | x |
| 2019-12-31 | $0.71 | $1.58 | x |
| 2020-12-31 | $0.78 | $1.58 | x |
| 2021-12-31 | $0.39 | $1.58 | x |
| 2022-12-31 | $0.21 | $1.58 | x |
| 2023-12-31 | $0.43 | $1.58 | x |
| 2024-12-31 | $0.43 | $1.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Geron Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -62.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -226.73%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 2.12x
- Recent ROE (-62.28%) is below the historical average (-56.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -45.34% | -201.89% | 0.18x | 1.22x | $-13.06 Million |
| 1997 | -45.50% | -131.51% | 0.28x | 1.24x | $-11.71 Million |
| 1998 | -32.93% | -158.82% | 0.15x | 1.36x | $-14.08 Million |
| 1999 | -177.10% | -859.26% | 0.08x | 2.43x | $-49.02 Million |
| 2000 | -71.71% | -693.49% | 0.06x | 1.78x | $-52.22 Million |
| 2001 | -68.36% | -1162.24% | 0.04x | 1.56x | $-48.23 Million |
| 2002 | -114.01% | -2716.99% | 0.02x | 2.04x | $-36.88 Million |
| 2003 | -28.11% | -2545.40% | 0.01x | 1.11x | $-40.52 Million |
| 2004 | -65.87% | -7635.80% | 0.01x | 1.08x | $-92.61 Million |
| 2005 | -17.58% | -11561.38% | 0.00x | 1.06x | $-52.60 Million |
| 2006 | -18.03% | -957.13% | 0.01x | 1.27x | $-48.76 Million |
| 2007 | -17.84% | -481.46% | 0.03x | 1.06x | $-57.26 Million |
| 2008 | -36.82% | -2212.67% | 0.02x | 1.05x | $-78.87 Million |
| 2009 | -40.67% | -4066.28% | 0.01x | 1.05x | $-87.44 Million |
| 2010 | -57.79% | -3125.93% | 0.02x | 1.21x | $-130.65 Million |
| 2011 | -66.06% | -3972.64% | 0.02x | 1.09x | $-111.51 Million |
| 2012 | -80.42% | -2542.67% | 0.03x | 1.17x | $-77.45 Million |
| 2013 | -64.23% | -2991.35% | 0.02x | 1.13x | $-44.35 Million |
| 2014 | -27.29% | -3093.67% | 0.01x | 1.32x | $-48.74 Million |
| 2015 | 0.03% | 0.13% | 0.24x | 1.05x | $-14.17 Million |
| 2016 | -24.14% | -479.34% | 0.05x | 1.06x | $-41.77 Million |
| 2017 | -26.89% | -2621.22% | 0.01x | 1.06x | $-38.30 Million |
| 2018 | -15.20% | -2534.43% | 0.01x | 1.04x | $-44.79 Million |
| 2019 | -47.02% | -13815.43% | 0.00x | 1.22x | $-77.07 Million |
| 2020 | -35.85% | -29888.14% | 0.00x | 1.28x | $-96.71 Million |
| 2021 | -91.85% | -8335.39% | 0.01x | 1.79x | $-128.75 Million |
| 2022 | -177.38% | -23808.89% | 0.00x | 2.38x | $-149.90 Million |
| 2023 | -74.26% | -77690.72% | 0.00x | 1.59x | $-208.92 Million |
| 2024 | -62.28% | -226.73% | 0.13x | 2.12x | $-202.60 Million |
Industry Comparison
This section compares Geron Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Geron Corporation (GERN) | $248.71 Million | -45.34% | 1.28x | $1.01 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.